How do we enable ultrasensitive biomarker quantitation? Here's our FAQ guide to Taudia's SPLASH Technology

Explore answers to common questions about our ultrasensitive workflows for blood-based biomarker detection for Alzheimer’s disease and beyond.

Who is Taudia?

We created a new blood-based biomarker quantitation platform technology focused on neurodegenerative diseases including Alzheimer’s disease (AD). Our wash-based, ultrasensitive assay provides reliable protein quantification of low-abundance protein biomarkers—empowering earlier, more accurate, and more accessible insights into disease progression.

Like in Alzheimer’s disease, many neurodegenerative diseases rely on expensive and invasive techniques such as imaging or cerebrospinal fluid testing for diagnosis. By contrast, blood-based biomarkers offer a simple, cost-effective, and scalable alternative. With Taudia’s assay, a routine blood draw can deliver clinically meaningful results in hours, not days. While Alzheimer’s disease has the most well-established clinical biomarkers, new biomarkers for other neurodegenerative diseases are being uncovered. Taudia is actively collaborating with researchers to develop blood-based tests for these novel biomarkers.

  • Our first product quantifies key AD biomarkers in blood, including: pTau-217, Aβ42 and Aβ40
  • Future development will expand into other general neurodegenerative disease biomarkers like NfL, GFAP, and other blood biomarkers.
  • Our menu will continue to expand as we begin to understand which biomarkers are critical in other diseases.
  • Taudia uses a wash-based immunoassay workflow that improves sensitivity and reproducibility:
    • Antibody binding: Modified antibodies form immunocomplexes with the protein of interest.
    • Wash step: Minimizes background interference for precision.
    • Quantitation: DNA tags are ligated and quantified via qPCR or dPCR.
    • Results: Delivered in less than four hours.
  • The available automated and benchtop workflow options ensure flexibility for everyone, enabling consistent, accessible, and ultrasensitive detection of blood biomarkers.

For biopharma and CROs, Taudia enables:

  • Patient screening: Identify MCl or early-stage AD patients accurately.
  • Scalability: Flexible with a fully automated sample-to-answer platform or a complete benchtop workflow with any qPCR instrument.
  • Reproducibility: Reduce variability with a standardized, automated workflow.
  • Companion diagnostics: Build reliable biomarker assays that accelerate therapeutic development.
  • Biopharma: For biomarker verification, patient enrollment, and companion diagnostic development.
  • Healthcare providers: To offer patients non-invasive, affordable, early AD blood test options.
  • Researchers: To quantify AD biomarkers with greater confidence and sensitivity.
  • We offer both a benchtop and fully automated workflow, so you can choose based on your lab setup and throughput needs.
  • Why both matter:
    • The benchtop option gives labs flexibility and provides a low barrier to entry while still offering ultrasensitive detection. You can get the same reliable results on any qPCR instrument.
    • The automated option accelerates workflows, reduces hands-on time, and reduces variation – especially vital for high-throughput research or clinical environments.
  • Maintaining brain health requires more than symptom checks. Emerging research shows that blood biomarker tracking can reveal changes in neural integrity long before clinical signs appear.
  • Key markers such as neurofilament light (NfL), β-synuclein, and glial fibrillary acidic protein (GFAP) reflect neuronal injury and glial response, offering a clearer view of brain aging and pathology than clinical evaluation alone.
  • Taudia’s ultrasensitive, flexible, and scalable platform is well-positioned to enable future blood tests that help people monitor trends, detect deviations, and act earlier to safeguard brain health.

We are currently offering early access programs. You can:

  • Partner with us to validate your biomarkers.
  • Pilot Taudia’s technology in your lab.
  • Contact us to discuss collaborations for clinical trials or diagnostic integration.